Robert W Keen, PA-C | |
145 Kimel Park Dr, Suite 330, Winston Salem, NC 27103-6984 | |
(336) 765-6181 | |
(336) 765-8492 |
Full Name | Robert W Keen |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 145 Kimel Park Dr, Winston Salem, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679527543 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0000X | Pain Medicine - Pain Medicine | 102964 (North Carolina) | Secondary |
363A00000X | Physician Assistant | 102964 (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Robert W Keen, PA-C 145 Kimel Park Dr, Suite 330, Winston Salem, NC 27103-6984 Ph: (336) 765-6181 | Robert W Keen, PA-C 145 Kimel Park Dr, Suite 330, Winston Salem, NC 27103-6984 Ph: (336) 765-6181 |
News Archive
Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced it has reached a joint venture agreement to begin production on a disposable protective face mask with its Asia Pacific region partner. The protective mask will incorporate ANI's proprietary NanoFenseā¢ technology, a U.S. patent pending antimicrobial nanoparticle formulation.
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.
T cells help fight off infection, but they can go overboard. A new study led by researchers at the University of Pennsylvania School of Dental Medicine and the National Institutes of Health shows that a subset of T cells contributes to the problematic inflammation and bone loss that is associated with periodontitis, a severe form of gum disease.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 3 days ago